DDInter1628 DDInter1925
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Ruxolitinib {u} (Compound) upregulates {v} (Gene) ZNF451
ZNF451 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Ruxolitinib {u} (Compound) downregulates {v} (Gene) KLHDC2
KLHDC2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Ruxolitinib {u} (Compound) binds {v} (Gene) CLK2
CLK2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Ruxolitinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Protein Kinase Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Vemurafenib
Ruxolitinib {u} (Compound) upregulates {v} (Gene) PPRC1
PPRC1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Ruxolitinib {u} (Compound) downregulates {v} (Gene) ZDHHC6
ZDHHC6 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Ruxolitinib {u} (Compound) upregulates {v} (Gene) ZNF451
ZNF451 {u} (Gene) regulates {v} (Gene) CRIP1
CRIP1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Ruxolitinib (Compound) upregulates ZNF451 (Gene) and ZNF451 (Gene) is upregulated by Vemurafenib (Compound)
Ruxolitinib (Compound) downregulates KLHDC2 (Gene) and KLHDC2 (Gene) is upregulated by Vemurafenib (Compound)
Ruxolitinib (Compound) binds CLK2 (Gene) and CLK2 (Gene) is upregulated by Vemurafenib (Compound)
Ruxolitinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class) and Protein Kinase Inhibitors (Pharmacologic Class) includes Vemurafenib (Compound)
Ruxolitinib (Compound) upregulates PPRC1 (Gene) and PPRC1 (Gene) is downregulated by Vemurafenib (Compound)
Ruxolitinib (Compound) downregulates ZDHHC6 (Gene) and ZDHHC6 (Gene) is downregulated by Vemurafenib (Compound)
Ruxolitinib (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Vemurafenib (Compound)
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Ruxolitinib (Compound) upregulates ZNF451 (Gene) and ZNF451 (Gene) regulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Vemurafenib (Compound)